latest news releases from the newsroom
GeneMedix plc: Quarter 3 Results for the Nine Months to August 31, 2002
SUFFOLK, U.K., Nov. 19, 2002 (PRIMEZONE) -- GeneMedix plc (LSE:GMX) ("GeneMedix" or "the Company"), the U.K. generic biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces its results for the 9 months to August 31, 2002. GeneMedix is involved in the development and manufacture of therapeutic proteins using recombinant DNA technology and novel cell culture.
`Waking Up...Alive': One woman's life lived through words
PORTLAND, Ore., November 18, 2002 (PRIMEZONE) -- You are about to be welcomed to the life of a woman who, through the vehicles of prose and poetry, shares her struggle to become a conscious human "being." She shares her hand-to-hand combat over time with ghosts who haunt her life, suck its energy and, daily, leave her feeling like she is pushing a rock uphill in her collection of prose and poetry entitled "Waking Up...Alive: A Prose and Poetry View of Life From the Inside Out" (now available through 1stBooks Library).
Crew Gold Corporation
Crew Development Corporation's Results for the Financial Year Ended June 30, 2002
VANCOUVER, British Columbia, Nov. 18, 2002 (PRIMEZONE) -- Crew Development Corporation (TSE:CRU) (OSLO:CRU) (FRANKFURT:KNC) (Other OTC:CRWVF) today announced that for the year ended June 30, 2002, the Company achieved operating income of CAD 20.2 million (2001 - CAD 9.2 million) on revenues of CAD 111.7 million (2001 - CAD 79.7 million). Also included in the results for the quarter are a provision for the impairment of CAD 19.6 million (2001 - CAD nil) in the value of the Company's investment in Asia Pacific Resources Ltd, and a provision of CAD 5 million (2001 - CAD nil) for the impairment of other mineral property interests, resulting in a net loss for the year ended June 30, 2002 of CAD 40.8 million (2001 - CAD 26.3 million).